What is Drug Benefit Integrity?
DBI is a structural standard for evaluating whether pharmacy benefit decisions are independently executed, verified, and documented. It moves beyond transparency - which shows what happened - to integrity - which ensures it happened right and provides independent proof.
DBI is not a product. It is not a company. It is a discipline - a set of requirements that any pharmacy benefit arrangement can be measured against. It draws from the same principles that govern financial services: the entity executing transactions on behalf of clients must demonstrate, through independent verification, that it acted in the client's interest.
Why Transparency Is Not Enough
The pharmacy benefits industry has responded to regulatory pressure with transparency. Report more. Disclose more. Show employers the data.
When the entity that made a routing decision also produces the report evaluating that decision, the evaluation - however accurate - is not independent. The same organization defined the options, selected the channel, and assessed whether the outcome was optimal.
Disclosing the details of a decision does not change the structure under which the decision was made. Transparency and independence serve different functions.
Even the most advanced transparent PBM models face this structural reality. When the entity reporting on decisions is also the entity that made them, the evaluation is not independent - regardless of its accuracy. Under increasing fiduciary scrutiny, that structural distinction matters.
The Regulatory Catalyst
- CAA 2026: 100% rebate pass-through, semiannual drug-level reporting, full audit rights, PBMs as ERISA covered service providers, $10,000/day noncompliance penalties
- FTC: Ongoing enforcement activity examining pharmacy benefit practices and market structure
- DOL: Proposed rule requiring detailed PBM compensation disclosure for self-funded ERISA plans
Plan fiduciaries now face personal liability for drug benefit decisions they have no independent means to verify.
The Financial Services Precedent
Financial services solved this decades ago. Independent clearing houses, independent auditors, best-execution standards enforced by third parties.
The concept that an entity executing financial transactions on behalf of clients must demonstrate - through independent verification - that it acted in the client's interest is foundational in finance.
Pharmacy benefits, at $400 billion a year, has no equivalent.
DBI Is Not Anti-PBM
Drug Benefit Integrity is designed to strengthen the position of every participant in the pharmacy benefit ecosystem.
A PBM that can point to an independent integrity layer demonstrating its dispensing channel decisions were optimal is in a stronger position - with clients, prospects, and regulators alike.
In an environment where consultants put transparent PBM alternatives on every finalist slate, independent verification may be the strongest competitive response available.
DBI does not replace PBMs. It introduces the independent verification layer that every other major financial system already requires. The PBMs that embrace Drug Benefit Integrity first will have a structural advantage.